Incyte (INCY) Q3 2026 Earnings Call Transcript
Incyte reported Q3 2026 revenue of $1.56B (+14% YoY). Jakafi sales were $827M (+4% YoY), while core business (ex-Jakafi) grew 30% to $490M. OPZELURA sales reached $255M (+36% YoY). The company highlighted regulatory milestones, pipeline advancements, and expects approvals for MONJUVI and povorcitinib in 2027. Incyte anticipates $3B-$4B in core business sales by 2030.
How this was made

The 30-second read
Why it matters
The call combines reported financial results with a concrete regulatory event (OPZELURA EU approval and launch) and specific pipeline timing (first 989 first-line MF data by year-end; FDA review of tafasitamab with expected approval in Q1 next year).
Market read
Traders can reassess Incyte’s near-term sales trajectory (OPZELURA and Jakafi) and the probability-weighted timing of regulatory and clinical catalysts into year-end and early next year.
What to watch
OPZELURA growth is partly driven by pricing dynamics tied to CMS agreements and settlements, which may introduce variability versus purely volume-led growth.
Background
The transcript frames Q3 performance around business execution, regulatory milestones, and late-stage pipeline progress.
Ticker impact
Incyte reports Q3 revenue of $1.56B, Jakafi net sales of $827M, and OPZELURA EU approval and launch, plus ongoing NDA reviews and pipeline updates.
Likely upward bias as investors price in stronger near-term sales momentum and incremental regulatory/clinical milestones.
The article includes multiple company-specific performance figures and a fresh regulatory milestone (OPZELURA EU approval and launch) alongside forward-looking clinical data timing (first 989 data by year-end).
Market effects
Reinforces sentiment for dermatology and hematology oncology franchises, particularly mutation-directed and JAK-adjacent therapies.
EU approval and launch of OPZELURA can improve regional revenue expectations and competitive positioning in Europe.
Highlights continued global expansion of Incyte’s hematology portfolio and pipeline progression that can influence biotech risk appetite.
Counterpoint
Despite strong reported growth, several key catalysts are still in review or early-stage (NDA reviews and late-stage trial timelines), so near-term upside may be capped until outcomes are clearer.
Key entities
- companyIncyte
Reports Q3 2026 results and discusses OPZELURA EU approval, Jakafi demand, and multiple late-stage pipeline milestones.
- productOPZELURA
Incyte’s therapy approved and launched in the EU for moderate AD in Q3, with reported net sales growth.
- productJakafi
Incyte’s JAK inhibitor with Q3 net sales of $827M and continued demand growth across indications.
- programMONJUVI
NDA review for frontline DLBCL is underway.
- programpovorcitinib
NDA review for moderate to severe HS is underway.


